SCHEMBL5543889

SCHEMBL5543889

CCOC(=O)c1ccc(CO[C]=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.61
CA2 P00918 4/20 0.61
CA12 O43570 3/20 0.61
CA7 P43166 3/20 0.61
CA9 Q16790 3/20 0.61
CA14 Q9ULX7 3/20 0.61
ESR1 P03372 1/20 0.61
ESR2 Q92731 1/20 0.61
LMNA P02545 1/20 0.54
CYP1A2 P05177 1/20 0.54
CYP3A4 P08684 1/20 0.54
MAOA P21397 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.53
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HTT P42858 4/20 0.51
MAPT P10636 2/20 0.50
HPGD P15428 4/20 0.49
NAMPT P43490 1/20 0.48
PKM P14618 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5540294 0.84 CA1 (0.53) CA1CA2CA12CA7CA9
SCHEMBL5546604 0.83 LOXL2 (0.58) CA1CA2CA12CA7CA9
SCHEMBL10821032 0.82 CA1 (0.69) CA1CA2CA12CA7CA9
SCHEMBL9710250 0.82 KMT2A (0.69) ESR1ESR2LMNASMN1; SMN2MEN1
SCHEMBL5546273 0.81 CYP4F2 (0.59) CA1CA2CA12CA7CA9
SCHEMBL5537903 0.81 CA1 (0.50) CA1CA2CA12CA7CA9
SCHEMBL14281812 0.81 CA12 (0.67) CA1CA2CA12CA7CA9
SCHEMBL10287538 0.81 CA12 (0.67) CA1CA2CA12CA7CA9
SCHEMBL128190 0.80 CA1 (0.70) CA1CA2CA12CA7CA9
SCHEMBL87450 0.80 CA1 (0.83) CA1CA2CA12CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CA1 3493/4885CA2 1853/4885CA12 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.